7/29/2013

A study in Diabetes Care showed patients who began treatment with insulin glargine had a nonsignificant 12% higher cancer incidence at one year compared with those on human neutral protamine Hagedorn insulin. Researchers also found women on glargine therapy for more than two years did not have a higher risk of breast cancer than those on NPH, while glargine-treated men had a nonsignificant 2.66-fold increased risk of prostate cancer at 12 to 24 months compared with the NPH group.

Related Summaries